CERVICAL CANCER SCREENING IN THE MODERN ERA: TECHNIQUES, GLOBAL BURDEN, AND IMPLEMENTATION CHALLENGES IN UZBEKISTAN

Meena Gyawali

Authors

Meena Gyawali MPH, MPRHGD, Asia International University, Bukhara, Uzbekistan

Keywords:

Cervical cancer, HPV, Pap smear, HPV DNA testing, screening, Uzbekistan, public health

Abstract

Cervical cancer is one of the leading causes of cancer-related morbidity and mortality among women worldwide, particularly in low- and middle-income countries. Persistent infection with high-risk human papillomavirus (HPV) plays a central role in cervical carcinogenesis. Modern screening techniques including Papanicolaou (Pap) smear cytology, HPV DNA testing, visual inspection with acetic acid (VIA), and co-testing have significantly improved early detection and prevention of cervical cancer. Despite global advances in screening and HPV vaccination, disparities remain in developing regions due to inadequate healthcare infrastructure, low awareness, and limited access to organized screening programs. Uzbekistan is gradually strengthening national cervical cancer prevention strategies; however, challenges related to screening coverage, diagnostic facilities, trained personnel, and public awareness continue to affect effective implementation. This review discusses contemporary cervical cancer screening methods, evaluates the global burden of disease, and analyzes the current status and implementation challenges of cervical cancer screening programs in Uzbekistan.

References

World Health Organization. Cervical cancer [Internet]. Geneva: WHO; 2024 [cited 2026 May 18]. Available from: https://www.who.int/health-topics/cervical-cancer

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265.

Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20):2101-2104.

IARC Working Group on the Evaluation of Cancer-Preventive Interventions. Cervical Cancer Screening. Lyon (FR): International Agency for Research on Cancer; 2022.

World Health Organization. New recommendations for screening and treatment to prevent cervical cancer [Internet]. Geneva: WHO; 2021 [cited 2026 May 18]. Available from: https://www.who.int/news/item/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer

World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.

Aniyozova D. National Programme on cervical cancer screening in the Republic of Uzbekistan: introduction of HPV based screening [Internet]. 2025 [cited 2026 May 18]. Available from: https://www.researchgate.net/publication/396245534_National_Programme_on_cervical_cancer_screening_in_the_Republic_of_Uzbekistan_introduction_of_HPV_based_screening

Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525-541.

International Agency for Research on Cancer. Worldwide burden of cancer attributable to HPV by site, country and HPV type [Internet]. Lyon: IARC; 2024 [cited 2026 May 18]. Available from: https://www.iarc.who.int/reference/worldwide-burden-of-cancer-attributable-to-hpv-by-site-country-and-hpv-type

Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis. 2020;24(2):102-131.

Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203.